Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to treat obesity on Wednesday, becoming a late contender in the race to offer a ...

Merck KGaA (Merck) and Opentrons Labworks have announced a partnership to automate assay kits on a ‘custom’ Opentrons Flex ...

Keytruda only uses the PD-1 pathway. Eliav Barr, chief medical officer at Merck Research Laboratories, said blocking both ...

Dean Li, president of Merck Research Laboratories, told the meeting that cardiovascular disease is a big opportunity as it remains an epidemic, killing 35 million people during the pandemic while ...

Merck Research Laboratories. “We look forward to advancing our research of this investigational ROR1-directed antibody drug conjugate, which we believe has strong potential in multiple ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

“We continue to leverage science-driven business development to augment and complement our robust pipeline,” said Dean Li, president of Merck Research Laboratories. “Through this ...

Merck Research Laboratories, said: “As part of Merck’s 30-year commitment to the care of people with HIV, we are pleased to now bring forward these two new antiretroviral treatment options ...

Merck Research Laboratories. “We continue to believe LAGEVRIO may be an important option for people with risk factors like older age, multiple comorbidities, and immunocompromising conditions ...

Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today announced it will collaborate with Merck as a premier platform to generate ...

Merck announced a weight loss drug deal Wednesday ... cardiometabolic benefits beyond weight reduction," said Merck Research Laboratories president Dr. Dean Y. Li in a statement.